Kenvue Inc. (NYSE:KVUE – Get Free Report) announced a quarterly dividend on Thursday, September 10th. Stockholders of record on Monday, September 21st will be given a dividend of 0.21 per share on Friday, October 2nd. This represents a c) dividend on an annualized basis and a dividend yield of 4.7%. The ex-dividend date is Monday, September 21st.
Kenvue has a dividend payout ratio of 68.9% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Kenvue to earn $1.23 per share next year, which means the company should continue to be able to cover its $0.84 annual dividend with an expected future payout ratio of 68.3%.
Kenvue Price Performance
KVUE opened at $17.73 on Friday. The company has a fifty day simple moving average of $19.05 and a 200 day simple moving average of $18.24. The firm has a market cap of $34.06 billion, a price-to-earnings ratio of 20.39, a PEG ratio of 1.59 and a beta of 0.46. Kenvue has a twelve month low of $14.02 and a twelve month high of $20.13. The company has a current ratio of 1.01, a quick ratio of 0.71 and a debt-to-equity ratio of 0.67.
About Kenvue
Kenvue Inc is a global consumer health company that develops, markets and sells products designed to support everyday health and personal care. Its portfolio spans over-the-counter medicines, skin health and beauty, essential health products, and baby and family care.
The company’s brands include Tylenol, Motrin, Zyrtec and Benadryl in self-care; Neutrogena, Aveeno and Clean & Clear in skin health and beauty; Listerine in oral care; and Johnson’s and Band-Aid in baby care and essential health.
See Also
- Five stocks we like better than Kenvue
- MarketBeat Week in Review – 09/07 – 09/11
- Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
- Kroger’s Textbook Entry for Buy-and-Hold Investors
- AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.
